Skip to content
Back to WVE

Wave Life Sciences, Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
51
Purchases
5
Sales
46
Purchase value
$82.55M
Sale value
$15.80M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

Adrian RawcliffeDirector
4Rule 10b5-1 plan disclosed
Filed Aug 13, 2026Period of report Aug 12, 20260001193125-26-349962
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 12, 2026
Common StockF1F212,700$5.29$67.18K0Direct
Filing footnotes · 2
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.
  2. F2The price reflected is the weighted-average sale price for stock sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $5.16 to $5.42 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
Heidi L WagnerDirector
4Rule 10b5-1 plan disclosed
Filed Aug 13, 2026Period of report Aug 11, 20260001193125-26-349963
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 11, 2026
Common StockF17,000$6.01$42.07K44,930Direct
Filing footnotes · 2
  1. F1The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.
  2. F2These stock options are fully vested.
Open on SEC EDGAR
KEN TakanashiDirector
4Rule 10b5-1 plan disclosed
Filed Aug 13, 2026Period of report Aug 11, 20260001193125-26-349961
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 11, 2026
Common StockF1F23,864$6.01$23.22K20,079Direct
Filing footnotes · 4
  1. F1On August 11, 2026, the reporting person sold 3,864 shares of common stock solely to cover taxes associated with the vesting of restricted stock units on August 11, 2026. These sales were made pursuant to a previously adopted 10b5-1 Trading Plan.
  2. F2The price reflected is the weighted-average sale price for stock sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $6.01 to $6.03 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  3. F3Includes an aggregate of (i) 6,107,593 shares of common stock held by SNBL USA, Ltd. ("SNBL USA") and (ii) 3,498,815 shares of common stock held by Shin Nippon Biomedical Laboratories, Ltd. ("SNBL").
  4. F4Ken Takanashi, a director of the Issuer, is a director of SNBL USA and SNBL and Mr. Takanashi may be deemed to beneficially own the reported securities held by SNBL USA and SNBL. Pursuant to Rule 16a-1 under the Securities Exchange Act of 1934, as amended (the "Act"), Mr. Takanashi disclaims beneficial ownership of the reported securities held by SNBL USA and SNBL, except to the extent of his pecuniary interest therein. The filing of this Form 4 shall not be construed as an admission that Mr. Takanashi is or was for the purposes of Section 16(a) of the Act, or otherwise, the beneficial owner of any of the reported securities held by SNBL USA or SNBL.
Open on SEC EDGAR
Aik Na TanDirector
4Rule 10b5-1 plan disclosed
Filed Aug 13, 2026Period of report Aug 11, 20260001193125-26-349960
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleAug 11, 2026
Common StockF1432$6.01$2.60K24,968Direct
Filing footnotes · 1
  1. F1On August 11, 2026, the reporting person sold 432 shares of common stock solely to cover taxes associated with the vesting of restricted stock units on August 11, 2026. These sales were made pursuant to a previously adopted 10b5-1 Trading Plan.
Open on SEC EDGAR
Peter KolchinskyDirector · 10% owner
Capital Healthcare Fund LP RADirector · 10% owner
L.P. RA Capital ManagementDirector · 10% owner
Rajeev M. ShahDirector · 10% owner
4
Filed Mar 30, 2026Period of report Mar 26, 20260001231919-26-000297
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMar 30, 2026
Ordinary SharesF6F2F3971,091$6.50$6.31M26,975,505IndirectSee footnotes
PurchaseMar 27, 2026
Ordinary SharesF5F2F32,495,623$6.43$16.05M26,004,414IndirectSee footnotes
PurchaseMar 26, 2026
Ordinary SharesF1F2F34,954,558$6.06$30.02M23,157,567IndirectSee footnotes
PurchaseMar 26, 2026
Ordinary SharesF4F2F3351,224$6.38$2.24M23,508,791IndirectSee footnotes
Filing footnotes · 8
  1. F1The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.365 to $6.36 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  2. F2RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
  3. F3Held directly by the Fund.
  4. F4The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.365 to $6.40 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  5. F5The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.09 to $6.74 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  6. F6The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $6.305 to $6.665 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.
  7. F7Represents previously reported restricted stock unit awards ("RSUs") granted to Dr. Kolchinsky and shares received by Dr. Kolchinsky upon settlement of RSUs.
  8. F8Dr. Kolchinsky is a Managing Partner of the Adviser who serves on the Issuer's board of directors. Under Dr. Kolchinsky's arrangement with the Adviser, Dr. Kolchinsky holds the RSUs and shares for the benefit of the Fund. Dr. Kolchinsky is obligated to turn over to the Adviser any net cash or shares received upon settlement of the RSUs, which will offset advisory fees owed by the Fund to the Adviser.
Open on SEC EDGAR
Chris FrancisSee Remarks
4Rule 10b5-1 plan disclosed
Filed Feb 27, 2026Period of report Feb 26, 20260001193125-26-083712
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 26, 2026
Ordinary SharesF1F417,900$15.094$270.18K61,867Direct
SaleFeb 26, 2026
Ordinary SharesF115,294$15.00$229.41K61,867Direct
Filing footnotes · 4
  1. F1The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.
  2. F2The option vests as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028.
  3. F3The option vests as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027.
  4. F4The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.00 to $15.10 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
Kyle MoranChief Financial Officer
4
Filed Feb 11, 2026Period of report Feb 5, 20260001193125-26-047323
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 9, 2026
Ordinary SharesF33,588$13.45$48.26K134,385Direct
Filing footnotes · 4
  1. F1Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.
  2. F2Includes 1,983 ordinary shares acquired on January 14, 2026, under the issuer's 2019 Employee Share Purchase Plan.
  3. F3On February 9, 2026, the reporting person sold 3,588 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.
  4. F4The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.
Open on SEC EDGAR
Paul BolnoDirector · President and CEO
4
Filed Feb 11, 2026Period of report Feb 5, 20260001193125-26-047322
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 9, 2026
Ordinary SharesF210,480$13.45$140.96K275,520Direct
Filing footnotes · 3
  1. F1Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.
  2. F2On February 9, 2026, the reporting person sold 10,480 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.
  3. F3The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.
Open on SEC EDGAR
Chris FrancisSee Remarks
4
Filed Feb 11, 2026Period of report Feb 5, 20260001193125-26-047319
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 9, 2026
Ordinary SharesF21,883$13.45$25.33K61,867Direct
Filing footnotes · 3
  1. F1Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.
  2. F2On February 9, 2026, the reporting person sold 1,883 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.
  3. F3The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.
Open on SEC EDGAR
Chandra VargeeseSee Remarks
4
Filed Feb 11, 2026Period of report Feb 5, 20260001193125-26-047314
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleFeb 9, 2026
Ordinary SharesF33,228$13.45$43.42K408,246Direct
Filing footnotes · 4
  1. F1Consists of restricted share units (RSUs). The RSUs vest in four equal annual installments of 25% on February 8, 2027 through February 8, 2030.
  2. F2Includes 3,162 ordinary shares acquired on July 15, 2025, and January 14, 2026, under the issuer's 2019 Employee Share Purchase Plan.
  3. F3On February 9, 2026, the reporting person sold 3,228 ordinary shares solely to cover taxes associated with the vesting of restricted share units ("RSUs") on February 8, 2026. These sales were made pursuant to a provision in the reporting person's RSU agreement that requires automatic sales of shares to cover tax withholding obligations.
  4. F4The option vests as to 25% of the shares on February 8, 2027, and vests as to an additional 6.25% of the shares quarterly thereafter until February 8, 2030.
Open on SEC EDGAR
Chris FrancisSee Remarks
4Rule 10b5-1 plan disclosed
Filed Jan 6, 2026Period of report Jan 2, 20260001193125-26-005195
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleJan 2, 2026
Ordinary SharesF1F38,080$15.92$128.63K26,295Direct
SaleJan 2, 2026
Ordinary SharesF1F41,295$16.70$21.63K25,000Direct
Filing footnotes · 4
  1. F1The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.
  2. F2These share options are fully vested.
  3. F3The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.56 to $16.54 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  4. F4The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $16.61 to $16.79 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
GSK PLC10% owner
4
Filed Dec 15, 2025Period of report Dec 11, 20250001999371-25-020336
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseDec 11, 2025
Ordinary SharesF11,470,000$19.00$27.93M18,245,691IndirectBy Corporation
Filing footnotes · 1
  1. F1The shares reported herein are held of record by Glaxo Group Limited, a wholly-owned subsidiary of GSK plc (the "Reporting Person").
Open on SEC EDGAR
Kyle MoranChief Financial Officer
4Rule 10b5-1 plan disclosed
Filed Dec 10, 2025Period of report Dec 8, 20250001193125-25-314736
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 9, 2025
Ordinary SharesF1F636$20.25$729.0089,218Direct
SaleDec 9, 2025
Ordinary SharesF1F6F750,000$20.025$1.00M90,365Direct
SaleDec 8, 2025
Ordinary SharesF160,000$13.20$792.00K89,218Direct
SaleDec 8, 2025
Ordinary SharesF1F450,000$15.00$750.00K139,218Direct
SaleDec 8, 2025
Ordinary SharesF150,000$13.20$660.00K89,218Direct
SaleDec 8, 2025
Ordinary SharesF150,000$18.00$900.00K89,218Direct
Filing footnotes · 7
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025.
  2. F2These share options are fully vested.
  3. F3The share option represented a right to purchase a total of 175,000 ordinary shares that vest as to 25% of the shares on January 1, 2023 and vests as to an additional 6.25% of the shares quarterly thereafter until January 1, 2026.
  4. F4The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $15.00 to $15.045 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  5. F5The share option represented a right to purchase a total of 272,200 ordinary shares that vest as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027.
  6. F6The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $20.00 to $20.22 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  7. F7Includes 1,147 ordinary shares acquired on July 14, 2025, under the issuer's 2019 Employee Share Purchase Plan.
Open on SEC EDGAR
Adrian RawcliffeDirector
4Rule 10b5-1 plan disclosed
Filed Dec 10, 2025Period of report Dec 8, 20250001193125-25-314742
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 8, 2025
Ordinary SharesF142,000$15.00$630.00K12,700Direct
Filing footnotes · 2
  1. F1The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.
  2. F2These share options are fully vested.
Open on SEC EDGAR
Heidi L WagnerDirector
4Rule 10b5-1 plan disclosed
Filed Dec 10, 2025Period of report Dec 8, 20250001193125-25-314741
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 8, 2025
Ordinary SharesF17,000$13.00$91.00K44,930Direct
SaleDec 8, 2025
Ordinary SharesF17,000$14.00$98.00K44,930Direct
Filing footnotes · 2
  1. F1The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025.
  2. F2These share options are fully vested.
Open on SEC EDGAR
Christian O HenryDirector
4Rule 10b5-1 plan disclosed
Filed Dec 10, 2025Period of report Dec 8, 20250001193125-25-314740
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 8, 2025
Ordinary SharesF16,445$12.75$82.17K12,700Direct
SaleDec 8, 2025
Ordinary SharesF142,000$12.75$535.50K12,700Direct
SaleDec 8, 2025
Ordinary SharesF1F315,000$14.07$211.05K12,700Direct
SaleDec 8, 2025
Ordinary SharesF1F430,000$18.02$540.60K12,700Direct
Filing footnotes · 4
  1. F1The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025.
  2. F2These share options are fully vested.
  3. F3The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.00 to $14.14 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  4. F4The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $18.00 to $18.19 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR
Aik Na TanDirector
4Rule 10b5-1 plan disclosed
Filed Dec 10, 2025Period of report Dec 8, 20250001193125-25-314739
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 8, 2025
Ordinary SharesF17,494$12.75$95.55K32,894Direct
SaleDec 8, 2025
Ordinary SharesF17,494$15.00$112.41K25,400Direct
SaleDec 8, 2025
Ordinary SharesF115,000$12.75$191.25K42,630Direct
SaleDec 8, 2025
Ordinary SharesF117,230$15.00$258.45K25,400Direct
SaleDec 8, 2025
Ordinary SharesF120,000$12.75$255.00K50,400Direct
SaleDec 8, 2025
Ordinary SharesF125,000$15.00$375.00K25,400Direct
SaleDec 8, 2025
Ordinary SharesF121,000$12.75$267.75K25,400Direct
SaleDec 8, 2025
Ordinary SharesF121,000$12.75$267.75K25,400Direct
Filing footnotes · 2
  1. F1The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025.
  2. F2These share options are fully vested.
Open on SEC EDGAR
Gregory L. VerdineDirector
4Rule 10b5-1 plan disclosed
Filed Dec 10, 2025Period of report Dec 8, 20250001193125-25-314738
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 8, 2025
Ordinary SharesF1F212,020$13.09$157.34K283,197Direct
SaleDec 8, 2025
Ordinary SharesF1F37,980$14.05$112.12K275,217Direct
Filing footnotes · 3
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 13, 2025.
  2. F2The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $12.75 to $13.74 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  3. F3The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $13.75 to $14.70 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price
Open on SEC EDGAR
Chris FrancisSee Remarks
4Rule 10b5-1 plan disclosed
Filed Dec 10, 2025Period of report Dec 8, 20250001193125-25-314737
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 8, 2025
Ordinary SharesF128,125$14.50$407.81K25,000Direct
SaleDec 8, 2025
Ordinary SharesF1F4107,400$14.556$1.56M25,000Direct
SaleDec 8, 2025
Ordinary SharesF145,882$14.50$665.29K25,000Direct
SaleDec 8, 2025
Ordinary SharesF19,375$15.00$140.63K25,000Direct
SaleDec 8, 2025
Ordinary SharesF137,500$14.08$528.00K25,000Direct
SaleDec 8, 2025
Ordinary SharesF117,900$15.00$268.50K25,000Direct
SaleDec 8, 2025
Ordinary SharesF1F6122,349$14.195$1.74M25,000Direct
SaleDec 8, 2025
Ordinary SharesF150,000$16.00$800.00K25,000Direct
SaleDec 8, 2025
Ordinary SharesF122,500$14.08$316.80K25,000Direct
Filing footnotes · 7
  1. F1The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 5, 2025.
  2. F2The share option represented a right to purchase a total of 150,000 ordinary shares that vest as to 25% of the shares on January 1, 2023 and vests as to an additional 6.25% of the shares quarterly thereafter until January 1, 2026.
  3. F3The share option represented a right to purchase a total of 286,400 ordinary shares that vest as to 25% of the shares on February 5, 2025, and vests as to an additional 6.25% of the shares quarterly thereafter until February 5, 2028.
  4. F4The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.50 to $14.78 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  5. F5The share option represented a right to purchase a total of 244,700 ordinary shares that vest as to 25% of the shares on February 17, 2024 and vests as to an additional 6.25% of the shares quarterly thereafter until February 17, 2027.
  6. F6The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $14.08 to $15.00 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  7. F7These share options are fully vested.
Open on SEC EDGAR
Mark CorriganDirector
4Rule 10b5-1 plan disclosed
Filed Dec 10, 2025Period of report Dec 8, 20250001193125-25-314735
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleDec 8, 2025
Ordinary SharesF1F29,600$13.09$125.66K35,330Direct
SaleDec 8, 2025
Ordinary SharesF1F36,515$14.065$91.63K28,815Direct
Filing footnotes · 3
  1. F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 6, 2025.
  2. F2The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $12.75 to $13.69 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
  3. F3The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $13.75 to $14.71 per share. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.